The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 08, 2019

Filed:

Oct. 05, 2011
Applicants:

Anastasios Lymperopoulos, Fort Lauderdale, FL (US);

Walter J. Koch, Philadelphia, PA (US);

Inventors:

Anastasios Lymperopoulos, Fort Lauderdale, FL (US);

Walter J. Koch, Philadelphia, PA (US);

Assignees:

NOVA SOUTHEASTERN UNIVERSITY, Fort Lauderdale, FL (US);

THOMAS JEFFERSON UNIVERSITY, Philadelphia, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 9/04 (2006.01); A61K 38/17 (2006.01); A61K 31/41 (2006.01); A61K 38/08 (2006.01); A61K 31/4184 (2006.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
A61K 38/085 (2013.01); A61K 31/41 (2013.01); A61K 31/4184 (2013.01); A61K 38/1709 (2013.01); A61P 9/04 (2018.01); C07K 14/4703 (2013.01);
Abstract

The invention concerns the contribution of elevated levels of circulating alsosterone to heart disease and other hyperaldosteronic conditions. Since activation of β-arrestin 1(βarr1) by the Angiotensin II (AngII) type 1 receptor (ATR) mediates AngII-induced aldosterone production, β-arrestin 1(βarr1) is a therapeutic target for heart disease. The invention provides a βarr1 protein fragment comprising the C-terminus of βarr1 (βarr1ct; SEQ ID NO:3), compositions containing this protein fragment, and methods of using this protein fragment to reduce elevated levels of aldosterone in heart disease and other hyperaldosteronic conditions by inhibition of β-arrestin 1(βarr1). These compositions and methods are of therapeutic benefit in chronic heart failure and progression to heart failure after myocardial infarction (MI). Additionally, the invention provides an AngII peptide analog (SEQ ID NO:4), compositions containing this analog, and methods of using this analog for stimulation of βarr1 activity and aldosterone production.


Find Patent Forward Citations

Loading…